Company Nymox Pharmaceutical Corporation Nasdaq
Equities
CA67076P1027
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Paul Averback
CEO | Chief Executive Officer | 73 | 29/05/95 |
Patrick Doody
BRD | Director/Board Member | - | 11/07/23 |
Director/Board Member | - | 20/03/23 | |
Suresh Kalbag
PRN | Corporate Officer/Principal | - | - |
General Counsel | - | 05/02/20 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
David S. Morse
BRD | Director/Board Member | 67 | 07/06/06 |
Paul Averback
CEO | Chief Executive Officer | 73 | 29/05/95 |
Director/Board Member | 88 | 30/06/15 | |
Director/Board Member | - | 20/03/23 | |
Patrick Doody
BRD | Director/Board Member | - | 11/07/23 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 93,265,000 | 54,049,529 ( 57.95 %) | 0 | 57.95 % |
Company contact information
Sector
Sales per region
1st Jan change | Capi. | |
---|---|---|
+26.43% | 52.73B | |
+37.49% | 39B | |
-9.24% | 38.52B | |
+29.16% | 30.38B | |
-12.26% | 26.39B | |
+10.71% | 26.08B | |
+45.10% | 14.15B | |
+32.34% | 12.6B | |
-6.01% | 11.51B |
- Stock Market
- Equities
- NYMXF Stock
- Stock
- Company Nymox Pharmaceutical Corporation